Skip to main
BNTX

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 23%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech is well-positioned for growth, evidenced by the promising results from BNT326 and its favorable comparison to competitive treatments in the EGFR+ NSCLC space, which underscores the potential for accelerated approval. The company's oncology pipeline, including innovative drug classes and strong early-phase efficacy results, reveals significant survival benefits, likely enhancing its market appeal as a fully integrated oncology company. Additionally, with a robust cash position of approximately €16.7 billion, BioNTech is financially equipped to support its development initiatives and capitalize on multiple upcoming catalysts.

Bears say

BioNTech is facing a negative outlook primarily due to anticipated declines in COVID-related revenues, which are projected to fall significantly over the coming years, leading to 24% and 18% reductions in fiscal years 2026 and 2025, respectively. Additionally, manufacturing challenges related to personalized therapeutics and potential negative data or slow market adoption for various oncology candidates could further impede the company’s revenue generation and impact future forecasts. The recent departure of key leadership figures, CEO Ugur Sahin and CMO Ozlem Tureci, also raises concerns about the company’s strategic direction and stability, contributing to a decline of over 20% in share value since the announcement.

BioNTech SE (BNTX) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 23% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 13 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $133.46, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $133.46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.